DDInter987 DDInter927
Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylephrine
Isoprenaline {u} (Compound) resembles {v} (Compound) Hexoprenaline
Isoprenaline {u} (Compound) resembles {v} (Compound) Isoetharine
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levonordefrin
Isoprenaline {u} (Compound) treats {v} (Disease) asthma
Isoprenaline {u} (Compound) binds {v} (Gene) PIK3R2
Isoprenaline {u} (Compound) upregulates {v} (Gene) DHX29
Isoprenaline {u} (Compound) downregulates {v} (Gene) COG2
Isoprenaline {u} (Compound) causes {v} (Side Effect) Flushing
Isoprenaline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ciclesonide
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine
Isoprenaline (Compound) resembles Hexoprenaline (Compound)
Isoprenaline (Compound) resembles Isoetharine (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Levonordefrin
Isoprenaline (Compound) treats asthma (Disease)
Isoprenaline (Compound) binds PIK3R2 (Gene)
Isoprenaline (Compound) upregulates DHX29 (Gene)
Isoprenaline (Compound) downregulates COG2 (Gene)
Isoprenaline (Compound) causes Flushing (Side Effect)
Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Ciclesonide